About Argenxargenx a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.
CEO: Tim Van Hauwermeiren
CFO: Eric Castaldi
CSO: Hans de Haard
CDO: Torsten Dreier
CMO: Nicolas Leupin
Please click here for Argenx job opportunities.
Please click here for clinical trial information.
134 articles with Argenx
All proposed resolutions on the agenda for this extraordinary shareholders' meeting were approved.
The event will feature guest speaker Dr. John Stanley, M.D., University of Pennsylvania School of Medicine, who will highlight the treatment landscape and unmet need in PV.
The first subject has been dosed in the Phase I clinical trial.
The company announced financial results and provided a business update for the third quarter ended September 30, 2017.
Argenx Launches Phase II Proof-Of-Concept Clinical Trial Of ARGX-113 For The Treatment Of Pemphigus Vulgaris
Argenx Announces Publication In Nature Medicine Of Preclinical Data Supporting The Therapeutic Potential Of SIMPLE Antibodytm ARGX-116 For The Treatment Of Dyslipidemia
Argenx To Host Conference Call & Webcast To Report Second Quarter Business Update And Half Year 2017 Financial Results On August 24, 2017
Argenx Presents Full Data From ARGX-111 Phase Ib Study In Patients With Advanced Cancers Over-Expressing The MET Protein At Best Of ASCO Asia 2017 (Singapore)